Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CN202 in advanced solid tumors or hematologic malignancies
NCT05028478Phase 2Unknown
- Sponsor
- Curon Biopharmaceutical
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of CN-202 in solid tumor, hematologic malignancy, sponsored by Curon Biopharmaceutical. Status: unknown.
02
Drugs
CN-202
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT05028478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028478.